Sign In
Buy PSTV
$5.42
-0.0500 (-0.91%)
At Close: Jun 03, 2026
Plus Therapeutics Shares Increase Over 20% Pre-Market: Why It Happened
06:13am, Monday, 23'rd Aug 2021
The shares of Plus Therapeutics, Inc. (Nasdaq: PSTV) increased by over 20% pre-market. This is why it happened.
Plus Therapeutics Announces Presentation of Data from the ReSPECT™-GBM Trial and Plans for Treating Pediatric Brain Cancer
09:24am, Saturday, 21'st Aug 2021
Data shows that the administration of Rhenium-186 NanoLiposome ( 186 RNL) via convection enhanced delivery for recurrent glioblastoma is well tolerated at significantly higher doses of radiotherapy th
Positive data to support FDA IND application for the clinical evaluation of Rhenium-186 Nanoliposome ( 186 RNL) targeted radiotherapy for patients with leptomeningeal metastases (LM)
AUSTIN, Texas, Aug. 13, 2021 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted therapies for rare
PSTV Stock Price Increased 11.23%: Why It Happened
05:27pm, Wednesday, 11'th Aug 2021
The stock price of Plus Therapeutics Inc (NASDAQ: PSTV) increased 11.23%. This is why it happened.
Plus Therapeutics to Present Data from Two Studies Supporting the Treatment of Leptomeningeal Metastases with Rhenium-186 Nanoliposome
10:12am, Wednesday, 11'th Aug 2021
AUSTIN, Texas, Aug. 11, 2021 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted therapies for rare
Plus Therapeutics to Present at Canaccord Genuity 41st Annual Growth Conference
07:30am, Thursday, 05'th Aug 2021
AUSTIN, Texas, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics
Plus Strengthens Commercial RNL Supply Chain with Ten Year Exclusivity Agreement
07:00am, Tuesday, 27'th Jul 2021
Global agreement covers 186 RNL manufacturing intermediate
Plus Therapeutics, Inc. (PSTV) CEO Marc Hedrick on Q2 2021 Results - Earnings Call Transcript
08:29pm, Thursday, 22'nd Jul 2021
Plus Therapeutics, Inc. (PSTV) CEO Marc Hedrick on Q2 2021 Results - Earnings Call Transcript
Plus Therapeutics Reports Second Quarter 2021 Financial Results and Business Highlights
04:05pm, Thursday, 22'nd Jul 2021
Management to host conference call today at 5:00 pm ET Management to host conference call today at 5:00 pm ET
PSTV Stock Increased Over 10% Intraday: Why It Happened
09:50am, Thursday, 22'nd Jul 2021
The stock price of Plus Therapeutics Inc (NASDAQ: PSTV) increased by over 10% during intraday trading. This is why it happened.
Plus Therapeutics Shares Jump As First Patient Treated In Latest Cohort Of Brain Tumor Trial
09:36am, Thursday, 22'nd Jul 2021
Plus Therapeutics Inc (NASDAQ: PSTV) has announced that the first patient in the eighth cohort of Phase 1 dose-escalation ReSPECT-GBM trial for recurrent glioblastoma (rGBM) has been treated. The
Plus Therapeutics to Announce Second Quarter 2021 Financial Results and Host Conference Call on July 22, 2021
07:30am, Thursday, 15'th Jul 2021
AUSTIN, Texas, July 15, 2021 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics
Plus Therapeutics Announces DSMB Approval to Proceed into Eighth Cohort in ReSPECT™ Glioblastoma Trial
07:30am, Wednesday, 16'th Jun 2021
AUSTIN, Texas, June 16, 2021 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing novel, targeted therapies for rare and
Plus Therapeutics Presents at the Sixth Biennial Pediatric Neuro-Oncology Research Conference
07:30am, Thursday, 10'th Jun 2021
AUSTIN, Texas, June 10, 2021 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company, today announced it will present a poster at the 6
